NIKKEI 225
38,703.51 +213.34 (+0.55%) HANG SENG
18,476.80 +51.84 (+0.28%) CRUDE OIL
75.56 +1.49 (+2.01%) GOLD FUTURES
2,389.70 +14.20 (+0.60%) DOW
38,791.11 -16.22 (-0.04%) Bitcoin GBP
55,527.36 -120.11 (-0.22%)
AGEN Nov 2024 10.000 call
| Previous close | 4.0000 |
| Open | 4.0000 |
| Bid | 9.0000 |
| Ask | 9.7000 |
| Strike | 10.00 |
| Expiry date | 2024-11-15 |
| Day's range | 4.0000 - 4.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 26 |
- Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
LEXINGTON, Mass., June 04, 2024--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.
- Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., May 24, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Eric Olson, in connection with his appointment as Head of Regulatory. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
- Business Wire
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
LEXINGTON, Mass., May 23, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced a novel analysis from the Phase 1b trial of botensilimab in combination with balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM) will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024. The ana
